Is Sandostatin Approved for Chronic Diarrhea?
Yes, Sandostatin (octreotide acetate) treats chronic diarrhea in specific cases, particularly diarrhea linked to carcinoid tumors or vasoactive intestinal peptide (VIP) tumors (VIPomas). It reduces hormone secretion that causes severe, refractory diarrhea unresponsive to other therapies.[1][2]
How Does Sandostatin Work for Diarrhea?
Sandostatin is a somatostatin analog that inhibits gastrointestinal hormone release, slowing gut motility and fluid secretion. Administered via subcutaneous injection (Sandostatin) or long-acting intramuscular depot (Sandostatin LAR), it controls symptoms in neuroendocrine tumors where diarrhea is a hallmark.[1][3]
What Conditions Qualify for Sandostatin Use?
FDA approval covers:
- Carcinoid syndrome diarrhea.
- VIPoma-related profuse watery diarrhea.
Off-label, it's used for chemotherapy-induced diarrhea, short bowel syndrome, or AIDS-related diarrhea, though evidence varies.[2][4]
Common Side Effects and Risks
Patients report gallstones (up to 60% with long-term use), injection-site pain, nausea, and bradycardia. Long-acting forms risk hyperglycemia or hypothyroidism. Monitor with regular ultrasounds and blood tests.[1][3]
Dosage for Diarrhea Treatment
Initial subcutaneous dose: 50-100 mcg 2-3 times daily, titrated up to 500 mcg per dose. Switch to LAR depot (10-30 mg monthly) once stabilized. Adjust based on symptom control.[1][2]
Alternatives to Sandostatin
| Treatment | Key Use | Comparison to Sandostatin |
|-----------|---------|---------------------------|
| Loperamide (Imodium) | Mild-moderate diarrhea | First-line, cheaper; less effective for tumor-related cases. |
| Telotristat ethyl (Xermelo) | Carcinoid diarrhea | Oral add-on; targets serotonin specifically. |
| Lanreotide (Somatuline) | Similar neuroendocrine tumors | Longer-acting competitor; similar efficacy.[4] |
Who Makes Sandostatin and Cost Factors
Novartis manufactures Sandostatin. Monthly LAR depot costs $5,000-$10,000 without insurance, varying by dose.[5] Patient assistance programs available via Novartis.
[1]: Sandostatin Prescribing Information (FDA)
[2]: Drugs.com - Sandostatin Uses
[3]: Medscape - Octreotide Dosing
[4]: UpToDate - Management of Malignant Intestinal Obstruction
[5]: GoodRx - Sandostatin Pricing